OccuLogix Effects Reverse Stock Split
08 10월 2008 - 5:30AM
Marketwired
OccuLogix, Inc. (NASDAQ: OCCX)(TSX: OC) announced that it has
effected a 1:25 reverse stock split of its common stock, as a
result of which every 25 issued and outstanding shares of common
stock has been combined into one share. No fractional share will be
issued as a result of the reverse stock split. Rather, stockholders
of the Company will receive a whole share in lieu of any fractional
share to which they might otherwise have been entitled.
OccuLogix's common stock will begin trading on a split-adjusted
basis on NASDAQ and the TSX, effective at the open of business on
Thursday, October 9, 2008. The letter "D" will be appended to
OccuLogix's NASDAQ ticker symbol, OCCX, for a period of 20 trading
days, after which time the letter "D" will be removed. The
Company's common stock will also trade under a new CUSIP
number.
The reverse stock split affects all of OccuLogix's issued and
outstanding shares of common stock, as well as the number of shares
issuable upon the exercise of outstanding stock options and
warrants.
The Company's stockholders of record will receive instructions
from the Company's transfer agent, Mellon Investor Services LLC,
regarding the procedures for exchanging their stock certificates in
connection with the reverse stock split. Those stockholders holding
their common stock in "street name" will receive instructions from
their brokerage firms if they need to take any action in connection
with the reverse stock split.
The Company's board of directors had recommended the reverse
stock split, in part, to help the Company regain compliance with
the $1.00 minimum bid price requirement for continued listing on
NASDAQ. OccuLogix's stockholders approved the reverse stock split
at the Annual and Special Meeting of Stockholders on September 30,
2008, and the Company's board of directors set the reverse split
ratio at 1:25 on that same day.
About OccuLogix, Inc.
OccuLogix (www.occulogix.com) is a healthcare company focused on
ophthalmic devices for the diagnosis and treatment of age-related
eye diseases. Its wholly-owned subsidiary, OcuSense, Inc.
(www.ocusense.com) is an ophthalmic device company developing and
commercializing novel, laboratory-on-a-card technologies that
enable eye care practitioners to test for highly sensitive and
specific biomarkers in tears at the point-of-care.
Forward-Looking Statements
This press release may contain forward-looking statements. These
statements relate to future events and are subject to risks,
uncertainties and assumptions about the Company. These statements
are only predictions based on our current expectations and
projections about future events. You should not place undue
reliance on these statements. Actual events or results may differ
materially. Many factors may cause our actual results to differ
materially from any forward-looking statement, including the
factors detailed in our filings with the Securities and Exchange
Commission and Canadian securities regulatory authorities,
including but not limited to our Forms 10-K and 10-Q. We do not
undertake to update any forward-looking statements.
Contacts: OccuLogix, Inc. Suh Kim (905) 602-0887, ext. 3915
Email: suh.kim@occulogix.com Website: www.occulogix.com
Occulogix (MM) (NASDAQ:OCCX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Occulogix (MM) (NASDAQ:OCCX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024